Avalo Therapeutics, Inc.
AVTX
$9.88
$0.515.44%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 441.00K | 441.00K | 441.00K | 820.00K | 807.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 441.00K | 441.00K | 441.00K | 820.00K | 807.00K |
| Cost of Revenue | 28.61M | 20.80M | 15.28M | 10.16M | 3.91M |
| Gross Profit | -28.17M | -20.36M | -14.84M | -9.34M | -3.10M |
| SG&A Expenses | 20.31M | 19.59M | 17.24M | 14.68M | 12.89M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 60.60M | 50.75M | 41.31M | 32.13M | 23.01M |
| Operating Income | -60.16M | -50.31M | -40.87M | -31.31M | -22.20M |
| Income Before Tax | -46.09M | 73.13M | -35.02M | -7.97M | -36.21M |
| Income Tax Expenses | 124.00K | 115.00K | 114.00K | -9.00K | 13.00K |
| Earnings from Continuing Operations | -46.22 | 73.01 | -35.13 | -7.96 | -36.22 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -46.22M | 73.01M | -35.13M | -7.96M | -36.22M |
| EBIT | -60.16M | -50.31M | -40.87M | -31.31M | -22.20M |
| EBITDA | -59.79M | -50.04M | -40.70M | -31.17M | -22.05M |
| EPS Basic | -5.62 | 0.51 | -29.87 | -36.55 | -64.37 |
| Normalized Basic EPS | -1.54 | 59.24 | -8.16 | -9.31 | -28.65 |
| EPS Diluted | -9.44 | -21.59 | -51.97 | -68.77 | -92.76 |
| Normalized Diluted EPS | -2.80 | 6.45 | -60.95 | -62.10 | -80.18 |
| Average Basic Shares Outstanding | 37.12M | 27.33M | 17.67M | 8.25M | 2.90M |
| Average Diluted Shares Outstanding | 42.36M | 39.18M | 29.53M | 20.10M | 9.52M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |